- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05396859
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
A Phase I Study of Entrectinib in Combination With ASTX727 (35 mg Decitabine and 100 mg Cedazuridine) in Patients With Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia (AML)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To determine the maximum tolerated dose (MTD) of decitabine and cedazuridine (ASTX727) combined with entrectinib in relapsed/refractory (R/R) AML patients with TP53 mutations.
SECONDARY OBJECTIVE:
I. To assess overall safety and preliminary anti-AML activity of combined ASTX727 and entrectinib regimen.
EXPLORATORY OBJECTIVE:
I. To assess the potential pharmacodynamic changes observed with treatment consisting of entrectinib alone and in combination with decitabine.
OUTLINE: This is a dose-escalation study of entrectinib.
Patients receive entrectinib orally (PO) once daily (QD) on days 1-28 and ASTX727 PO QD on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 3 months for up to 1 year.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- OHSU Knight Cancer Institute
-
Contact:
- Ronan T. Swords, M.D.
- Phone Number: 503-494-9014
- Email: swords@ohsu.edu
-
Principal Investigator:
- Ronan T. Swords, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Must be able to understand and willing to sign an informed consent document.
- Participants aged 18 years or older.
- Morphologically documented AML in patients with relapsed/refractory disease, defined as having >= 20% blasts in bone marrow or peripheral blood.
- Documented TP53 mutation as seen on standard diagnostics in AML.
- Aspartate aminotransferase (AST) < 3 × upper limit of normal (ULN).
- Alanine aminotransferase (ALT) < 3 × ULN.
- Total bilirubin < 1.5 × ULN (except for patients with known Gilbert's syndrome).
- Adequate renal function as defined by calculated creatinine clearance (according to the Cockcroft-Gault equation) > 40 mL/min OR serum creatinine < 1.5 × ULN.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) =< 2.
- Must be able to take oral medication.
- Individuals of childbearing potential (IOCBP) must agree to use highly-effective method(s) of contraception during the study and six months after the last dose of study drugs. IOCBP must have a negative pregnancy test prior to study enrollment.
- Sperm producing individuals must agree to use an adequate method of contraception starting with the first dose of study therapy through 3 months after the last dose of study drugs.
- Participants must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of their cancer.
Exclusion Criteria:
- Isolated myeloid sarcoma (patients must have blood or marrow involvement with AML to enter the study).
- Acute promyelocytic leukemia (M3).
- Active central nervous system (CNS) involvement by AML.
- Clinical signs/symptoms of leukostasis which has failed urgent therapy of at least 3 days duration, which may have included hydroxyurea or leukapheresis.
- Known active human immunodeficiency virus (HIV), active hepatitis B or active hepatitis C infection.
- Disseminated intravascular coagulopathy with active bleeding or signs of thrombosis.
- Patients who have received an investigational agent (for any indication) within 5 half-lives of the agent or who have agent-related toxicity that has not resolved to grade 1 or less. If the half-life of an investigational agent is unknown, patients must wait 1 week after discontinuing it before receiving the first dose of study treatment. An investigational agent is one for which there is no approved indication by the United States (US) Food and Drug Administration (FDA).
- Prior entrectinib for other malignancies (prior decitabine therapy will not be excluded).
- Patients with psychological, familial, social, or geographic factors that otherwise preclude them from giving informed consent, following the protocol, or potentially hamper compliance with study treatment and follow-up.
- Patients who are otherwise felt unable to comply with the protocol, in the opinion of the investigator.
- Any other significant medical condition, including psychiatric illness or laboratory abnormality, that would preclude the patient participating in the trial or would confound the interpretation of the results of the trial.
- Patients with the following will be excluded: uncontrolled intercurrent illness including, but not limited to, symptomatic (New York Heart Association [NYHA] class III or IV) congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, myocardial infarction at presentation of AML, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Patients with medical comorbidities that will preclude safety evaluation of the combination should not be enrolled.
- Patients with uncontrolled infection shall not be enrolled until infection is treated and controlled.
- Participants with prior documented history of malabsorption syndrome (e.g., short gut syndrome) that might limit the bioavailability of study medications will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (ASTX727, entrectinib)
Patients receive entrectinib PO QD on days 1-28 and ASTX727 PO QD on days 1-5.
Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Given PO
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of dose limiting toxicities (DLTs)
Time Frame: From first dose of study drug (day 1 of cycle 0) to end of cycle 1 (each cycle = 28 days)
|
Toxicities will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version [v] 5.0).
|
From first dose of study drug (day 1 of cycle 0) to end of cycle 1 (each cycle = 28 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-related grade >= 3 adverse events
Time Frame: From first dose of study drug (day 1 of cycle 0) up to 30 days post end of therapy (each cycle = 28 days)
|
Treatment-related grade >= 3 adverse events will be tallied and summarized for the entire safety analysis set and within subgroups defined by each participant's assigned entrectinib dose level.
AE tabulations will be constructed at both the participant-level and the event-level, with each toxicity summarized by grade (i.e., severity), duration, and system organ class.
AE incidence will be reported using frequency counts and percentages with 95% exact binomial confidence intervals (CIs).
|
From first dose of study drug (day 1 of cycle 0) up to 30 days post end of therapy (each cycle = 28 days)
|
Composite complete remission (CCR) rate
Time Frame: From first dose of study drug up to 2 weeks after last dose of study drug, start of new cancer therapy, or transplant, end of study follow up, death (whichever is first), assessed up to 6 months
|
cCR is defined as the proportion of participants who attain a best response of Complete Remission with incomplete blood count recovery (CRi), Complete Remission (CR), or Complete Remission with Minimal Residual Disease (CRMRD) per 2017 European LeukemiaNet (ELN).
Each response endpoint will be computed for both the safety analysis set and the efficacy analysis set, with a fraction's numerator equaling the number of participants achieving the requisite degree of response and the denominator comprising the number of participants in the respective analysis set.
|
From first dose of study drug up to 2 weeks after last dose of study drug, start of new cancer therapy, or transplant, end of study follow up, death (whichever is first), assessed up to 6 months
|
Overall response rate (ORR)
Time Frame: From first dose of study drug up to 2 weeks after last dose of study drug, start of new cancer therapy, or transplant (whichever is first), assessed up to 6 months
|
Each response endpoint will be computed for both the safety analysis set and the efficacy analysis set, with a fraction's numerator equaling the number of participants achieving the requisite degree of response and the denominator comprising the number of participants in the respective analysis set.
|
From first dose of study drug up to 2 weeks after last dose of study drug, start of new cancer therapy, or transplant (whichever is first), assessed up to 6 months
|
Clinical benefit rate (CBR)
Time Frame: From first dose of study drug up to 2 weeks after last dose of study drug, start of new cancer therapy, or transplant (whichever is first), assessed up to 6 months
|
Each response endpoint will be computed for both the safety analysis set and the efficacy analysis set, with a fraction's numerator equaling the number of participants achieving the requisite degree of response and the denominator comprising the number of participants in the respective analysis set.
|
From first dose of study drug up to 2 weeks after last dose of study drug, start of new cancer therapy, or transplant (whichever is first), assessed up to 6 months
|
Proportion transplanted
Time Frame: From first dose of study drug up to end of follow-up or death, assessed up to 6 months
|
The proportion of participants in the safety analysis set who transition to stem cell transplantation will be computed and reported as a percentage with a 95% exact CI.
|
From first dose of study drug up to end of follow-up or death, assessed up to 6 months
|
Duration of response (DOR)
Time Frame: From first dose of study drug up to end of follow-up, loss of partial response (PR), progression or death (whichever is first), assessed up to 6 months
|
Will be estimated by the Kaplan-Meier method and reported with the median and rates at various landmark times (e.g., 3 months, 6 months, 1 year), each accompanied with a 95% complementary log-log CI.
|
From first dose of study drug up to end of follow-up, loss of partial response (PR), progression or death (whichever is first), assessed up to 6 months
|
Event free survival (EFS)
Time Frame: From first dose of study drug up to end of follow-up, relapse, progression, start of new cancer therapy, study drug discontinuation due to toxicity or death (whichever is first), assessed up to 6 months
|
Will be estimated by the Kaplan-Meier method and reported with the median and rates at various landmark times (e.g., 3 months, 6 months, 1 year), each accompanied with a 95% complementary log-log CI.
|
From first dose of study drug up to end of follow-up, relapse, progression, start of new cancer therapy, study drug discontinuation due to toxicity or death (whichever is first), assessed up to 6 months
|
Overall survival (OS)
Time Frame: From first dose of study drug up to end of follow-up or death, assessed up to 6 months
|
Will be estimated by the Kaplan-Meier method and reported with the median and rates at various landmark times (e.g., 3 months, 6 months, 1 year), each accompanied with a 95% complementary log-log CI.
|
From first dose of study drug up to end of follow-up or death, assessed up to 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Genomic analysis
Time Frame: Pre-dose Cycle 0; At Cycle 1 day 1; Cycle 1, Day 8; Cycle 1, Day 28 (each cycle = 28 days)
|
Expression or intensity changes will be modeled with a paired t-test, linear mixed effects model, or marginal model using a generalized estimating equation.
|
Pre-dose Cycle 0; At Cycle 1 day 1; Cycle 1, Day 8; Cycle 1, Day 28 (each cycle = 28 days)
|
Total NTRK protein levels
Time Frame: Pre-dose Cycle 0; At Cycle 1 day 1; Cycle 1, Day 8; Cycle 1, Day 28 (each cycle = 28 days)
|
Expression or intensity changes will be modeled with a paired t-test, linear mixed effects model, or marginal model using a generalized estimating equation.
|
Pre-dose Cycle 0; At Cycle 1 day 1; Cycle 1, Day 8; Cycle 1, Day 28 (each cycle = 28 days)
|
NTRK phosphorylation levels
Time Frame: Pre-dose Cycle 0; At Cycle 1 day 1; Cycle 1, Day 8; Cycle 1, Day 28 (each cycle = 28 days)
|
Expression or intensity changes will be modeled with a paired t-test, linear mixed effects model, or marginal model using a generalized estimating equation.
|
Pre-dose Cycle 0; At Cycle 1 day 1; Cycle 1, Day 8; Cycle 1, Day 28 (each cycle = 28 days)
|
RUNX1 protein levels
Time Frame: Pre-dose Cycle 0; At Cycle 1 day 1; Cycle 1, Day 8; Cycle 1, Day 28 (each cycle = 28 days)
|
Expression or intensity changes will be modeled with a paired t-test, linear mixed effects model, or marginal model using a generalized estimating equation.
|
Pre-dose Cycle 0; At Cycle 1 day 1; Cycle 1, Day 8; Cycle 1, Day 28 (each cycle = 28 days)
|
ERK1/2 phosphorylation levels
Time Frame: Pre-dose Cycle 0; At Cycle 1 day 1; Cycle 1, Day 8; Cycle 1, Day 28 (each cycle = 28 days)
|
Expression or intensity changes will be modeled with a paired t-test, linear mixed effects model, or marginal model using a generalized estimating equation.
|
Pre-dose Cycle 0; At Cycle 1 day 1; Cycle 1, Day 8; Cycle 1, Day 28 (each cycle = 28 days)
|
NTRK gene expression
Time Frame: Pre-dose Cycle 0; At Cycle 1 day 1; Cycle 1, Day 8; Cycle 1, Day 28 (each cycle = 28 days)
|
Expression or intensity changes will be modeled with a paired t-test, linear mixed effects model, or marginal model using a generalized estimating equation.
|
Pre-dose Cycle 0; At Cycle 1 day 1; Cycle 1, Day 8; Cycle 1, Day 28 (each cycle = 28 days)
|
RUNX1 gene expression
Time Frame: Pre-dose Cycle 0; At Cycle 1 day 1; Cycle 1, Day 8; Cycle 1, Day 28 (each cycle = 28 days)
|
Expression or intensity changes will be modeled with a paired t-test, linear mixed effects model, or marginal model using a generalized estimating equation.
|
Pre-dose Cycle 0; At Cycle 1 day 1; Cycle 1, Day 8; Cycle 1, Day 28 (each cycle = 28 days)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ronan T Swords, M.D., OHSU Knight Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Hematologic Diseases
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Decitabine
- Entrectinib
- Decitabine and cedazuridine drug combination
Other Study ID Numbers
- STUDY00023205 (Other Identifier: OHSU Knight Cancer Institute)
- NCI-2022-02156 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Advesya SASNot yet recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryFrance, Sweden, Spain, Germany
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States